- Volpara enters into a five-year contract with the US outpatient diagnostics imaging provider worth US$2.15 million.
- Volpara would install its Patient Hub software across 11 states where the imaging centres are located.
- The software would enable its customers to have a standardised patient tracking system.
The ASX-listed healthcare company Volpara Health Technologies Limited (ASX:VHT) announced that it has entered into a contract with a leading US outpatient diagnostic imaging provider worth US$2.15 million, representing US$430 thousand ARR. VHT shared that it is one of the highest-value contracts signed to date.
The term of the contract is five years.
About the contract:
As per the contract, Volpara would install its Patient Hub software across the customer’s extensive network of imaging centres located in 11 states. This would enable the customers to have a standardised patient tracking platform for their patients, including Volpara Risk and Scorecard—the most clinically validated density software available today. This will also allow the customer to triage each patient accurately into the appropriate personalised breast cancer screening pathway.
Volpara Health Technologies Limited is a leading healthcare company that is originally based in New Zealand. It aims to provide personalised breast cancer screening solutions by developing cutting-edge innovations. The Company has a global presence in North America, South America, Europe, Asia, Middle East and New Zealand.
Meanwhile, on the ASX, the VHT stock was spotted trading 2.543% lower at AU$1.150 per share at 11:03 AM AEST.
The highest-value contract signed by Volpara seems highly significant for the Company. Volpara’s best version of patient tracking, risk assessment, and density scoring is likely to offer its customers to provide their patients with the individualised care best suited for each one of them.